Isoquinolone Compounds as Subtype-Selective Agonists for Melatonin Receptors MT1 and MT2具選擇性褪黑素受體亞型激動劑活性的新穎異喹諾酮化合物
- 总结
- Melatonin has been implicated in the regulation of a number of physiological processes and, thus, has been used in the treatment of various biological disorders. It is widely used in the treatment of chronobiological disorders such as seasonal affective disorders (SAD), primary and secondary insomnia, and sleep disorders caused by blindness, shift work (Sack et al., 1992) and jet lag. Melatonin has also been linked to retinal physiology, blood pressure regulation, and in the regulation of the immune system, inflammation, and cancer and tumor growth.
The invention relates to isoquinolone derivatives and their use as therapeutic agents. In particular, the invention relates to isoquinolone compounds that are capable of modulating melatonin receptors and to pharmaceutical compositions containing such compounds for treating disorders or pathological conditions associated with melatonin receptors in mammalian subjects.
- 技术优势
- Malatonin is not sub-type specific and despite its modulatory effects on various effector systems, has a short biological half-life, poor oral bioavailability and exhibits ubiquitous action. The compounds of current invention are more potent and stable than melatonin since they also exhibit selectivity towards each melatonin receptor sub-type.
- 技术应用
- Potential drug candidate for treating jet-lag, seasonal affective disorders, insomnia, circadian-related disorders and may also covering other pathophysiological conditions such as inflammation, tumour growth and neurodegenerative diseases.
- 附加资料
- Patent Number: CN101583601B
Application Number: CN200780050054A
Inventor: NEW, DAVID CHARLES | HE, Jue-zhong | HU, Yue-qing | HE, Xi-xin | PANG, Hai-hong | WANG, Yin-hou
Priority Date: 17 Jan 2007
Priority Number: CN101583601B
Application Date: 17 Jan 2007
Publication Date: 5 Jun 2013
IPC Current: C07D021708 | A61K00314704 | A61K0031472 | A61K00314725 | A61P000912 | A61P002500 | A61P002508 | A61P002518 | A61P002528 | A61P002900 | A61P003500 | C07D021724
Assignee Applicant: The Hong Kong University of Science & Technology
Title: Isoquinolone compounds as subtype-selective agonists for melatonin receptors mt1 and mt2 | Melatonin receptor MT 1 and MT 2 a subtype selective agonist of cefquinome ketone compound
Usefulness: Isoquinolone compounds as subtype-selective agonists for melatonin receptors mt1 and mt2 | Melatonin receptor MT 1 and MT 2 a subtype selective agonist of cefquinome ketone compound
Summary: For treating, preventing or ameliorating a pathological condition associated with a melatonin receptor; for modulating an activity of a melatonin receptor (claimed). The conditions associated with a melatonin receptor includes biological disorders such as seasonal affective disorders, primary and secondary insomnia, sleep disorders caused by blindness; in retinal physiology; in blood pressure regulation; in regulation of immune system; for treating inflammation, cancer, tumor growth; for inhibiting growth and progression of variety of tumor cells including breast cancer, ovarian carcinoma, endometrial carcinoma, melanoma, prostate tumor and intestinal tumor cells; in the treatment of psychiatric disorders such as bipolar, depression and anxiety disorders, schizophrenia, epilepsy and epileptic seizures, neurodegenerative disorders (such as Parkinson's disease, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, muscular sclerosis), stroke and neuroendocrine disorders such as peptic ulceration and psoriasis.
Novelty: Use of old and new isoquinolone derivatives for treating or ameliorating pathological condition associated with melatonin receptor e.g. seasonal affective disorders, primary and secondary insomnia and sleep disorders caused by blindness
- 主要类别
- 诊断/治疗
- 细分类别
- 癌症/肿瘤
- 申请日期
- 17 Jul 2009
- 申请号码
- Chinese 200780050054.7
- 专利信息
- Chinese ZL200780050054.7
- ID号码
- TTC.PA.287
- 国家/地区
- 香港
欲了解更多信息，请点击 这里
